110 related articles for article (PubMed ID: 25533501)
1. The comparison of BLyS-binding peptides from phage display library and computer-aided design on BLyS-TACI interaction.
Zhao Y; Hao X; Feng J; Shen B; Wei J; Sun J
Int Immunopharmacol; 2015 Feb; 24(2):219-223. PubMed ID: 25533501
[TBL] [Abstract][Full Text] [Related]
2. An optimized B lymphocyte stimulator (BLyS) antagonist peptide inhibits the interaction of BLyS with BCMA.
Tian Y; Zhu YF; Wu Z; Feng JN; Li Y; Shen BF; Sun J
Biotechnol Lett; 2013 Apr; 35(4):523-8. PubMed ID: 23242501
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Biological Activity of B Lymphocyte Stimulator (BLyS) Antagonist Peptibodies and the Elucidation of Possible BLyS Binding Sites.
Hao X; Zhu Y; Zheng C; Fu X; Feng J; Shen B; Wei J
Protein Pept Lett; 2016; 23(1):17-23. PubMed ID: 26497318
[TBL] [Abstract][Full Text] [Related]
4. Discovery of high-affinity peptide binders to BLyS by phage display.
Fleming TJ; Sachdeva M; Delic M; Beltzer J; Wescott CR; Devlin M; Lander RC; Nixon AE; Roschke V; Hilbert DM; Sexton DJ
J Mol Recognit; 2005; 18(1):94-102. PubMed ID: 15382264
[TBL] [Abstract][Full Text] [Related]
5. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS.
Wu Y; Bressette D; Carrell JA; Kaufman T; Feng P; Taylor K; Gan Y; Cho YH; Garcia AD; Gollatz E; Dimke D; LaFleur D; Migone TS; Nardelli B; Wei P; Ruben SM; Ullrich SJ; Olsen HS; Kanakaraj P; Moore PA; Baker KP
J Biol Chem; 2000 Nov; 275(45):35478-85. PubMed ID: 10956646
[TBL] [Abstract][Full Text] [Related]
7. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI.
Liu W; Szalai A; Zhao L; Liu D; Martin F; Kimberly RP; Zhou T; Carter RH
Arthritis Rheum; 2004 Jun; 50(6):1884-96. PubMed ID: 15188365
[TBL] [Abstract][Full Text] [Related]
8. Expression and characterization of a variant of TACI (CRD2-shortTACIFc) in Pichia pastoris.
Wang R; Zhou S; Peng X; Zhou XW; Xie ZQ; Wang Y; Mo W; Yu M
Protein Pept Lett; 2012 Mar; 19(3):315-25. PubMed ID: 21933134
[TBL] [Abstract][Full Text] [Related]
9. TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice.
Moon EY; Ryu SK
Exp Mol Med; 2007 Jun; 39(3):343-52. PubMed ID: 17603288
[TBL] [Abstract][Full Text] [Related]
10. [Isolation of a novel peptide that binds to BLyS from a 12-mer phage display peptide library].
Ding YL; Han W; Shen Q; Liu H; Yang SL; Gong Y
Yi Chuan; 2006 Feb; 28(2):208-11. PubMed ID: 16520318
[TBL] [Abstract][Full Text] [Related]
11. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
[TBL] [Abstract][Full Text] [Related]
12. Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS).
Gor DO; Ding X; Li Q; Sultana D; Mambula SS; Bram RJ; Greenspan NS
Biol Direct; 2011 Feb; 6():9. PubMed ID: 21306646
[TBL] [Abstract][Full Text] [Related]
13. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
14. Generation of a fusion protein of the extracellular domain of BR3 with the Fc fragment of human IgG1 (sBR3-Fc) in Pichia pastoris as an antagonist for BLyS.
Cao P; Zhang S; Fang Z; Huang H; Bai P; Zhang Q; Luo C
Appl Microbiol Biotechnol; 2008 Feb; 78(2):275-82. PubMed ID: 18189138
[TBL] [Abstract][Full Text] [Related]
15. Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model.
Bath NM; Ding X; Wilson NA; Verhoven BM; Boldt BA; Sukhwal A; Reese SR; Panzer SE; Djamali A; Redfield RR
PLoS One; 2019; 14(2):e0211865. PubMed ID: 30735519
[TBL] [Abstract][Full Text] [Related]
16. Effect of TACI signaling on humoral immunity and autoimmune diseases.
Zhang Y; Li J; Zhang YM; Zhang XM; Tao J
J Immunol Res; 2015; 2015():247426. PubMed ID: 25866827
[TBL] [Abstract][Full Text] [Related]
17. A novel BLyS antagonist peptide designed based on the 3-D complex structure of BCMA and BLyS.
Sun J; Feng J; Li Y; Shen B
Biochem Biophys Res Commun; 2006 Aug; 346(4):1158-62. PubMed ID: 16793005
[TBL] [Abstract][Full Text] [Related]
18. [The immunopotentiation of human B lymphocyte stimulator C-terminal peptide].
Tian RY; Han W; Yu Y; Chen Y; Yu GS; Yang SL; Gong Y
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Dec; 35(12):1128-32. PubMed ID: 14673506
[TBL] [Abstract][Full Text] [Related]
19. The effect of BLyS on the activity of peripheral B lymphocytes mediated by BLyS receptors in patients with systemic lupus erythematosus.
Cheng Y; Yan S; Zhao W; Huang Q; Lian L; Wei W
Scand J Clin Lab Invest; 2013 Mar; 73(2):141-7. PubMed ID: 23336587
[TBL] [Abstract][Full Text] [Related]
20. [Screening of antagonist peptide of BLyS from C7C phage display peptide library].
Ji Q; He FT; Li RF; Gao HG; Zheng YR; Zhong XL; Zheng HQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jul; 20(4):398-401. PubMed ID: 15207079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
